The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Apellis Pharmaceuticals Inc COM 03753U106 894 50,290 SH   SOLE   50,290 0 0
Bellerophon Therapeutics COM 078771102 2,456 2,274,370 SH   SOLE   2,274,370 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 23,356 3,061,091 SH   SOLE   3,061,091 0 0
ChemoCentryx Inc COM 16383L106 493 39,036 SH   SOLE   39,036 0 0
Constellation Pharmaceuticals COM 210373106 449 66,667 SH   SOLE   66,667 0 0
Endocyte Inc COM 29269A102 10,656 600,000 SH   SOLE   600,000 0 0
Gemphire Therapeutics COM 36870A108 1,791 869,538 SH   SOLE   869,538 0 0
Kadmon Holdings Inc. COM 48283N106 7,978 2,388,572 SH   SOLE   2,388,572 0 0
Kalvista Pharmaceuticals COM 483497103 28,410 1,284,931 SH   SOLE   1,284,931 0 0
Kiniksa Pharmaceuticals Ltd COM G5269C101 8,358 327,777 SH   SOLE   327,777 0 0
Marinus Pharmaceuticals Inc COM 56854Q101 6,723 672,271 SH   SOLE   672,271 0 0
Obseva SA COM H5861P103 20,911 1,159,789 SH   SOLE   1,159,789 0 0
Tricida Inc COM 89610F101 19,875 650,585 SH   SOLE   650,585 0 0